{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T17:18:42Z","timestamp":1790615922238,"version":"4.1.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterology Clinics of North America"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.gtc.2021.10.007","type":"journal-article","created":{"date-parts":[[2022,1,8]],"date-time":"2022-01-08T00:55:39Z","timestamp":1641603339000},"page":"107-121","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Opioid-Related Constipation"],"prefix":"10.1016","volume":"51","author":[{"given":"Joy J.","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren M.","family":"Brenner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.gtc.2021.10.007_bib1","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1053\/j.gastro.2020.09.041","article-title":"Epidemiologic burden and treatment of chronic symptomatic functional bowel disorders in the United States: a nationwide analysis","volume":"160","author":"Ma","year":"2021","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.gtc.2021.10.007_bib2","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1053\/j.gastro.2019.12.021","article-title":"Prevalence of Rome IV Functional Bowel Disorders Among Adults in the United States, Canada, and the United Kingdom","volume":"158","author":"Palsson","year":"2020","journal-title":"Gastroenterology"},{"issue":"15","key":"10.1016\/j.gtc.2021.10.007_bib3","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1001\/jama.2016.1464","article-title":"CDC guideline for prescribing opioids for chronic pain--United States, 2016","volume":"315","author":"Dowell","year":"2016","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.gtc.2021.10.007_bib4","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1053\/j.gastro.2016.02.031","article-title":"Bowel Disorders","volume":"150","author":"Lacy","year":"2016","journal-title":"Gastroenterology"},{"issue":"10","key":"10.1016\/j.gtc.2021.10.007_bib5","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1111\/nmo.12417","article-title":"Emerging treatments in neurogastroenterology: a multidisciplinary working group consensus statement on opioid-induced constipation","volume":"26","author":"Camilleri","year":"2014","journal-title":"Neurogastroenterol Motil"},{"issue":"3","key":"10.1016\/j.gtc.2021.10.007_bib6","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s11894-017-0560-2","article-title":"Opioid-related constipation in patients with non-cancer pain syndromes: a review of evidence-based therapies and justification for a change in nomenclature","volume":"19","author":"Brenner","year":"2017","journal-title":"Curr Gastroenterol Rep"},{"issue":"3","key":"10.1016\/j.gtc.2021.10.007_bib7","doi-asserted-by":"crossref","first-page":"307","DOI":"10.14309\/ajg.0000000000000496","article-title":"How to manage opioid-related constipation in individuals with chronic nonmalignant pain syndromes","volume":"115","author":"Brenner","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gtc.2021.10.007_bib8","doi-asserted-by":"crossref","unstructured":"Brenner D, Chey W. An Evidence-Based Review of Novel and Emerging Therapies for Constipation in Patients Taking Opioid Analgesics. In: 2014. doi:10.1038\/AJGSUP.2014.8.","DOI":"10.1038\/ajgsup.2014.8"},{"key":"10.1016\/j.gtc.2021.10.007_bib9","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1526-4637.2008.00495.x","article-title":"The prevalence, severity, and impact of opioid-induced bowel dysfunction: Results of a US and European Patient Survey (PROBE 1)","volume":"10","author":"Bell","year":"2009","journal-title":"Pain Med"},{"issue":"4","key":"10.1016\/j.gtc.2021.10.007_bib10","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1177\/2050640616659967","article-title":"Prevalence and clinical features of opioid-induced constipation in the general population: A French study of 15,000 individuals","volume":"5","author":"Ducrott\u00e9","year":"2017","journal-title":"United Eur Gastroenterol J"},{"issue":"1","key":"10.1016\/j.gtc.2021.10.007_bib11","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s00535-013-0753-x","article-title":"Physiology, signaling, and pharmacology of opioid receptors and their ligands in the gastrointestinal tract: current concepts and future perspectives","volume":"49","author":"Sobczak","year":"2014","journal-title":"J\u00a0Gastroenterol"},{"issue":"11","key":"10.1016\/j.gtc.2021.10.007_bib12","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.14309\/ajg.0000000000000413","article-title":"Is Dyssynergic Defecation an Unrecognized Cause of Chronic Constipation in Patients Using Opioids?","volume":"114","author":"Nojkov","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gtc.2021.10.007_bib13","article-title":"Morphine induces changes in the gut microbiome and metabolome in a morphine dependence model","volume":"8","author":"Wang","year":"2018","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.gtc.2021.10.007_bib14","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/s40122-020-00195-z","article-title":"What to do and what not to do in the management of opioid-induced constipation: a choosing wisely report","volume":"9","author":"Alvaro","year":"2020","journal-title":"Pain Ther"},{"issue":"5","key":"10.1016\/j.gtc.2021.10.007_bib15","first-page":"889","article-title":"Analysis of Patient-Provider Interactions Regarding the Burden and Treatment of Opioid-Induced Constipation in Adults with Chronic Noncancer Pain","volume":"20","author":"Vallerand","year":"2019","journal-title":"Pain Med Malden Mass"},{"key":"10.1016\/j.gtc.2021.10.007_bib16","article-title":"Management of Opioid-Induced Constipation in Hospice Patients","author":"Sera","year":"2017","journal-title":"Am J Hosp Palliat Med"},{"issue":"9","key":"10.1016\/j.gtc.2021.10.007_bib17","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1097\/AJP.0000000000000852","article-title":"Opioid-induced constipation: a review of health-related quality of life, patient burden, practical clinical considerations, and the impact of peripherally acting \u03bc-opioid receptor antagonists","volume":"36","author":"Argoff","year":"2020","journal-title":"Clin J Pain"},{"issue":"12","key":"10.1016\/j.gtc.2021.10.007_bib18","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1111\/pme.12937","article-title":"Consensus recommendations on initiating prescription therapies for opioid-induced constipation","volume":"16","author":"Argoff","year":"2015","journal-title":"Pain Med"},{"issue":"4","key":"10.1016\/j.gtc.2021.10.007_bib19","first-page":"371","article-title":"Validation of the Bowel Function Index to detect clinically meaningful changes in opioid-induced constipation","volume":"12","author":"Rentz","year":"2009","journal-title":"J\u00a0Med Econ"},{"issue":"Suppl 2","key":"10.1016\/j.gtc.2021.10.007_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41395-018-0084-x","article-title":"American College of Gastroenterology monograph on management of irritable bowel syndrome","volume":"113","author":"Ford","year":"2018","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"10.1016\/j.gtc.2021.10.007_bib21","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1053\/j.gastro.2018.08.018","article-title":"American Gastroenterological Association Institute Technical Review on the Medical Management of Opioid-Induced Constipation","volume":"156","author":"Hanson","year":"2019","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.gtc.2021.10.007_bib22","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1053\/j.gastro.2018.07.016","article-title":"American Gastroenterological Association Institute guideline on the medical management of opioid-induced constipation","volume":"156","author":"Crockett","year":"2019","journal-title":"Gastroenterology"},{"issue":"10","key":"10.1016\/j.gtc.2021.10.007_bib23","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1155\/2014\/631740","article-title":"Systematic review of stimulant and nonstimulant laxatives for the treatment of functional constipation","volume":"28","author":"Par\u00e9","year":"2014","journal-title":"Can J Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.gtc.2021.10.007_bib24","doi-asserted-by":"crossref","first-page":"954","DOI":"10.14309\/ajg.0000000000000229","article-title":"A\u00a0randomized, multicenter, prospective, crossover, open-label study of factors associated with patient preferences for naloxegol or PEG 3350 for opioid-induced constipation","volume":"114","author":"Brenner","year":"2019","journal-title":"Am J Gastroenterol"},{"issue":"5A Suppl","key":"10.1016\/j.gtc.2021.10.007_bib25","doi-asserted-by":"crossref","first-page":"11S","DOI":"10.1016\/S0002-9610(01)00782-6","article-title":"Incidence, prevalence, and management of opioid bowel dysfunction","volume":"182","author":"Pappagallo","year":"2001","journal-title":"Am J Surg"},{"key":"10.1016\/j.gtc.2021.10.007_bib26","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.sjpain.2015.12.007","article-title":"Opioid-induced constipation, use of laxatives, and health-related quality of life","volume":"11","author":"Christensen","year":"2016","journal-title":"Scand J Pain"},{"key":"10.1016\/j.gtc.2021.10.007_bib27","doi-asserted-by":"crossref","first-page":"269","DOI":"10.2147\/CEOR.S61602","article-title":"Opioid-induced constipation in patients with chronic noncancer pain in the USA, Canada, Germany, and the UK: descriptive analysis of baseline patient-reported outcomes and retrospective chart review","volume":"6","author":"Coyne","year":"2014","journal-title":"Clin Outcomes Res"},{"issue":"2","key":"10.1016\/j.gtc.2021.10.007_bib28","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1097\/AJP.0000000000000662","article-title":"Clinical Overview and Considerations for the Management of Opioid-induced Constipation in Patients With Chronic Noncancer Pain","volume":"35","author":"Viscusi","year":"2019","journal-title":"Clin J Pain"},{"issue":"5","key":"10.1016\/j.gtc.2021.10.007_bib29","first-page":"554","article-title":"Subcutaneous methylnaltrexone for treatment of opioid-induced constipation in patients with chronic, nonmalignant pain: a randomized controlled study","volume":"12","author":"Michna","year":"2011","journal-title":"J\u00a0Pain"},{"issue":"8","key":"10.1016\/j.gtc.2021.10.007_bib30","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1111\/j.1526-4637.2011.01189.x","article-title":"Efficacy of Subcutaneous Methylnaltrexone in the Treatment of Opioid-Induced Constipation: A Responder Post Hoc Analysis","volume":"12","author":"Michna","year":"2011","journal-title":"Pain Med"},{"issue":"6","key":"10.1016\/j.gtc.2021.10.007_bib31","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1111\/papr.12535","article-title":"Randomized, Double-Blind Trial of Oral Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Patients with Chronic Noncancer Pain","volume":"17","author":"Rauck","year":"2017","journal-title":"Pain Pract"},{"issue":"8","key":"10.1016\/j.gtc.2021.10.007_bib32","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1093\/pm\/pnx148","article-title":"Long-term safety and efficacy of subcutaneous methylnaltrexone in patients with opioid-induced constipation and chronic noncancer pain: a phase 3, open-label trial","volume":"18","author":"Webster","year":"2017","journal-title":"Pain Med"},{"key":"10.1016\/j.gtc.2021.10.007_bib33","first-page":"139","article-title":"Safety of oral methylnaltrexone for opioid-induced constipation in patients with chronic noncancer pain","volume":"12","author":"Rauck","year":"2018","journal-title":"J\u00a0Pain Res"},{"key":"10.1016\/j.gtc.2021.10.007_bib34","unstructured":"Movantik (naloxegol) Prescribing Information. Published online 2014. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/204760s000lbl.pdf."},{"issue":"25","key":"10.1016\/j.gtc.2021.10.007_bib35","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1310246","article-title":"Naloxegol for Opioid-Induced Constipation in Patients with Noncancer Pain","volume":"370","author":"Chey","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.gtc.2021.10.007_bib36","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/apt.12899","article-title":"Randomised clinical trial: the long-term safety and tolerability of naloxegol in patients with pain and opioid-induced constipation","volume":"40","author":"Webster","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gtc.2021.10.007_bib37","first-page":"195","article-title":"Spotlight on naldemedine in the treatment of opioid-induced constipation in adult patients with chronic noncancer pain: design, development, and place in therapy","volume":"11","author":"Stern","year":"2018","journal-title":"J\u00a0Pain Res"},{"key":"10.1016\/j.gtc.2021.10.007_bib38","doi-asserted-by":"crossref","DOI":"10.2217\/pmt-2020-0019","article-title":"Naldemedine for the treatment of opioid-induced constipation in adults with chronic noncancer pain","author":"Liu","year":"2020","journal-title":"Pain Manag"},{"issue":"8","key":"10.1016\/j.gtc.2021.10.007_bib39","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S2468-1253(17)30105-X","article-title":"Naldemedine versus placebo for opioid-induced constipation (COMPOSE-1 and COMPOSE-2): two multicentre, phase 3, double-blind, randomised, parallel-group trials","volume":"2","author":"Hale","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.gtc.2021.10.007_bib40","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1097\/j.pain.0000000000001174","article-title":"Long-term use of naldemedine in the treatment of opioid-induced constipation in patients with chronic noncancer pain: a randomized, double-blind, placebo-controlled phase 3 study","volume":"159","author":"Webster","year":"2018","journal-title":"Pain"},{"issue":"5","key":"10.1016\/j.gtc.2021.10.007_bib41","doi-asserted-by":"crossref","first-page":"C1173","DOI":"10.1152\/ajpcell.00528.2003","article-title":"SPI-0211 activates T84 cell chloride transport and recombinant human ClC-2 chloride currents","volume":"287","author":"Cuppoletti","year":"2004","journal-title":"Am J Physiol Cell Physiol"},{"issue":"11","key":"10.1016\/j.gtc.2021.10.007_bib42","first-page":"1825","article-title":"A\u00a0randomized study of lubiprostone for opioid-induced constipation in patients with chronic noncancer pain","volume":"15","author":"Cryer","year":"2014","journal-title":"Pain Med Malden Mass"},{"issue":"6","key":"10.1016\/j.gtc.2021.10.007_bib43","first-page":"1184","article-title":"Efficacy and Safety of Lubiprostone in Patients with Opioid-Induced Constipation: Phase 3 Study Results and Pooled Analysis of the Effect of Concomitant Methadone Use on Clinical Outcomes","volume":"19","author":"Spierings","year":"2018","journal-title":"Pain Med Malden Mass"},{"issue":"5","key":"10.1016\/j.gtc.2021.10.007_bib44","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/ajg.2015.106","article-title":"A\u00a0randomized, placebo-controlled trial of lubiprostone for opioid-induced constipation in chronic noncancer pain","volume":"110","author":"Jamal","year":"2015","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"10.1016\/j.gtc.2021.10.007_bib45","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s12013-012-9406-6","article-title":"Methadone but not morphine inhibits lubiprostone-stimulated Cl- currents in T84 intestinal cells and recombinant human ClC-2, but not CFTR Cl- currents","volume":"66","author":"Cuppoletti","year":"2013","journal-title":"Cell Biochem Biophys"},{"issue":"6","key":"10.1016\/j.gtc.2021.10.007_bib46","first-page":"1195","article-title":"Efficacy of Lubiprostone for the Treatment of Opioid-Induced Constipation, Analyzed by Opioid Class","volume":"19","author":"Webster","year":"2018","journal-title":"Pain Med Malden Mass"},{"issue":"5","key":"10.1016\/j.gtc.2021.10.007_bib47","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1097\/j.pain.0000000000001754","article-title":"Efficacy and safety of linaclotide for opioid-induced constipation in patients with chronic noncancer pain syndromes from a phase 2 randomized study","volume":"161","author":"Brenner","year":"2020","journal-title":"Pain"},{"issue":"10","key":"10.1016\/j.gtc.2021.10.007_bib48","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1007\/s10620-010-1229-y","article-title":"Efficacy and Safety of Prucalopride in Patients with Chronic Noncancer Pain Suffering from Opioid-Induced Constipation","volume":"55","author":"Sloots","year":"2010","journal-title":"Dig Dis Sci"},{"issue":"10","key":"10.1016\/j.gtc.2021.10.007_bib49","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/j.cgh.2018.01.021","article-title":"Efficacy of Treatments for Opioid-Induced Constipation: Systematic Review and Meta-analysis","volume":"16","author":"Nee","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.gtc.2021.10.007_bib50","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1136\/gutjnl-2018-316001","article-title":"Efficacy of pharmacological therapies for the treatment of opioid-induced constipation: systematic review and network meta-analysis","volume":"68","author":"Luthra","year":"2019","journal-title":"Gut"},{"issue":"4","key":"10.1016\/j.gtc.2021.10.007_bib51","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1177\/1060028017739637","article-title":"Evidence Based Review of Pharmacotherapy for Opioid-Induced Constipation in Noncancer Pain","volume":"52","author":"Murphy","year":"2018","journal-title":"Ann Pharmacother"},{"issue":"4","key":"10.1016\/j.gtc.2021.10.007_bib52","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/cpdd.335","article-title":"An Open-Label, Randomized Bioavailability Study of Alternative Methods of Oral Administration of Naloxegol in Healthy Subjects","volume":"6","author":"Bui","year":"2017","journal-title":"Clin Pharmacol Drug Dev"}],"container-title":["Gastroenterology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889855321007342?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889855321007342?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:38:36Z","timestamp":1760179116000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889855321007342"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["S0889855321007342"],"URL":"https:\/\/doi.org\/10.1016\/j.gtc.2021.10.007","relation":{},"ISSN":["0889-8553"],"issn-type":[{"value":"0889-8553","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Opioid-Related Constipation","name":"articletitle","label":"Article Title"},{"value":"Gastroenterology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gtc.2021.10.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}